logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Chronic Heart Failure

    FiltersReset Filters
    3 results

    • carvedilol

      (Carvedilol)
      Zydus Pharmaceuticals USA Inc.
      Usage: Carvedilol is indicated for treating mild-to-severe chronic heart failure, reducing cardiovascular mortality in stable post-myocardial infarction patients with left ventricular dysfunction, and managing essential hypertension, either alone or in combination with other antihypertensive agents.

    • corlanor

      (ivabradine)
      Amgen Inc
      Usage: Corlanor is indicated to reduce hospitalization risk for adults with stable, symptomatic chronic heart failure (left ventricular ejection fraction ≤ 35%) and resting heart rate ≥ 70 bpm. It is also used for pediatric patients aged 6 months and older with stable symptomatic heart failure due to dilated cardiomyopathy.

    • entresto

      (Sacubitril and Valsartan)
      Novartis Pharmaceuticals Corporation
      Usage: ENTRESTO is indicated for reducing cardiovascular death and hospitalization in adults with chronic heart failure, particularly those with reduced left ventricular ejection fraction. It is also used to treat symptomatic heart failure in pediatric patients aged one year and older, aiming to improve cardiovascular outcomes.